Akebia Therapeutics Inc.
AKBA
Market Cap$291.03M
Close$
$2.57
89.1% upside
Current Fair Value
89.1% upsideUndervalued by 89.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $291.03 Million |
|---|---|
| Enterprise Value | $291.73 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.28 |
| Beta | 1.21 |
| Outstanding Shares | 209,372,275 |
| Avg 30 Day Volume | 8,980,550 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.6 |
|---|---|
| PEG | 5.63 |
| Price to Sales | - |
| Price to Book Ratio | -1.36 |
| Enterprise Value to Revenue | 1.5 |
| Enterprise Value to EBIT | -6.33 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | -1.43 |
Revenue Sources
No data
ESG Score
No data
About Akebia Therapeutics Inc.
CEO: John Butler